Χώρα: Σιγκαπούρη
Γλώσσα: Αγγλικά
Πηγή: HSA (Health Sciences Authority)
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE EQV SALMETEROL
GLAXOSMITHKLINE PTE LTD
R03AK06
250 mcg/inhalation
POWDER, METERED
FLUTICASONE PROPIONATE 250 mcg/inhalation; SALMETEROL XINAFOATE EQV SALMETEROL 50 mcg/inhalation
RESPIRATORY (INHALATION)
Prescription Only
GlaxoSmithKline LLC
ACTIVE
1999-07-19
1 SERETIDE TM ACCUHALER TM Salmeterol / fluticasone propionate QUALITATIVE AND QUANTITATIVE COMPOSITION Moulded plastic device containing a foil strip with 60 regularly placed blisters each containing 50 mcg of salmeterol (as salmeterol xinafoate) and 100 mcg of fluticasone propionate. Moulded plastic device containing a foil strip with 60 regularly placed blisters each containing 50 mcg of salmeterol (as salmeterol xinafoate) and 250 mcg of fluticasone propionate. Moulded plastic device containing a foil strip with 60 regularly placed blisters each containing 50 mcg of salmeterol (as salmeterol xinafoate) and 500 mcg of fluticasone propionate. PHARMACEUTICAL FORM Inhalation powder. CLINICAL PARTICULARS INDICATIONS Seretide is indicated in the regular treatment of asthma where use of a combination (bronchodilator and inhaled corticosteroid) has been found to be appropriate. Seretide is indicated for the symptomatic treatment of patients with severe COPD (FEV1 <50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular bronchodilator therapy. DOSAGE AND ADMINISTRATION Seretide Accuhaler is for oral inhalation only. Patients should be made aware that Seretide Accuhaler must be used regularly for optimum benefit, even when asymptomatic. Patients should be regularly reassessed by a doctor, so that the strength of Seretide they are receiving remains optimal and is only changed on medical advice. ASTHMA The dose should be titrated to the lowest dose at which effective control of symptoms is maintained. 2 Patients should be given the strength of Seretide containing the appropriate fluticasone propionate dosage for the severity of their disease. If a patient is inadequately controlled on inhaled corticosteroid t Διαβάστε το πλήρες έγγραφο
1 SERETIDE ACCUHALER Salmeterol / fluticasone propionate QUALITATIVE AND QUANTITATIVE COMPOSITION Moulded plastic device containing a foil strip with 60 regularly placed blisters each containing 50 mcg of salmeterol (as salmeterol xinafoate) and 100 mcg of fluticasone propionate. Moulded plastic device containing a foil strip with 60 regularly placed blisters each containing 50 mcg of salmeterol (as salmeterol xinafoate) and 250 mcg of fluticasone propionate. Moulded plastic device containing a foil strip with 60 regularly placed blisters each containing 50 mcg of salmeterol (as salmeterol xinafoate) and 500 mcg of fluticasone propionate. CLINICAL INFORMATION INDICATIONS Pharmaceutical form: Inhalation powder. Seretide is indicated in the regular treatment of asthma where use of a combination (bronchodilator and inhaled corticosteroid) has been found to be appropriate. Seretide is indicated for the symptomatic treatment of patients with severe COPD (FEV 1 <50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular bronchodilator therapy. DOSAGE AND ADMINISTRATION Seretide Accuhaler is for oral inhalation only. Patients should be made aware that Seretide Accuhaler must be used regularly for optimum benefit, even when asymptomatic. Patients should be regularly reassessed by a doctor, so that the strength of Seretide they are receiving remains optimal and is only changed on medical advice. ASTHMA The dose should be titrated to the lowest dose at which effective control of symptoms is maintained. 2 Patients should be given the strength of Seretide containing the appropriate fluticasone propionate dosage for the severity of their disease. If a patient is inadequately controlled on inhaled corticosteroid therapy alone, substitution with Seretide at a therapeutically equivalent corticosteroid dose may result in an improvement in asthma control. Recommended Doses: Adults and adolescents 12 years and older: One inhalation (50 mcg salmeterol and 100 mcg fluticasone propiona Διαβάστε το πλήρες έγγραφο